Key facts
- AngioGenex, Inc. has 4 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 4 Insiders of AngioGenex, Inc.
- Location
- New York, NY
Change
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 21 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
AngioGenex, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Michael M. Strage | Vice President, Director, 10%+ Owner | Mixed | 31 Dec 2021 | |||
| Michael Aronstein | Director, CHAIRMAN, 10%+ Owner | Mixed | 31 Dec 2021 | |||
| Robert Dickey IV | Director, INDEPENDENT DIRECTOR | Mixed | 31 Dec 2021 | |||
| Martin Murray | Secretary, Treasurer, CFO, Director | Mixed | 31 Dec 2021 |
Top shareholders of AngioGenex, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Michael Aronstein |
3/4/5
|
Director, CHAIRMAN, 10%+ Owner |
—
mixed-class rows
|
17,747,827
mixed-class rows
|
— | — | 31 Dec 2021 | |
| Michael M. Strage |
3/4/5
|
Vice President, Director, 10%+ Owner |
—
mixed-class rows
|
7,376,347
mixed-class rows
|
— | — | 31 Dec 2021 | |
| Robert Dickey IV |
3/4/5
|
Director, INDEPENDENT DIRECTOR |
—
class O/S missing
|
850,000
|
— | — | 31 Dec 2021 | |
| Martin Murray |
3/4/5
|
Secretary, Treasurer, CFO, Director |
—
class O/S missing
|
125,000
|
— | — | 31 Dec 2021 |
Recent Insider Transactions by Companies or Individuals for AngioGenex, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.